The role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies

References

• Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1982;79(24):7824–7827.
   PubMed Web of Science ®Google Scholar
• Calado DP, Sasaki Y, Godinho SA, et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol. 2012;13(11):1092–1100.
   PubMed Web of Science ®Google Scholar
• Dominguez-Sola D, Victora GD, Ying CY, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol. 2012;13(11):1083–1091.
   PubMed Web of Science ®Google Scholar
• Luo W, Weisel F, Shlomchik MJ. B cell receptor and CD40 signaling are rewired for synergistic induction of the c-Myc transcription factor in germinal center B cells. Immunity. 2018;48(2):313–326.e5.
   PubMed Web of Science ®Google Scholar
• Bisso A, Sabò A, Amati B. MYC in germinal center‐derived lymphomas: mechanisms and therapeutic opportunities. Immunol Rev. 2019;288(1):178–197.
   PubMed Web of Science ®Google Scholar
• De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15(3):137–148.
   PubMed Web of Science ®Google Scholar
• Basso K, Saito M, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115(5):975–984.
   PubMed Web of Science ®Google Scholar
• Nahar R, Ramezani-Rad P, Mossner M, et al. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011;118(15):4174–4178.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. Genes. 2017;8(4):116.
   PubMed Web of Science ®Google Scholar
• Lin Y. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997;276(5312):596–599.
   PubMed Web of Science ®Google Scholar
• Amati B, Brooks MW, Levy N, et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72(2):233–245.
   PubMed Web of Science ®Google Scholar
• Nikiforov MA, Chandriani S, Park J, et al. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol Cell Biol. 2002;22(14):5054–5063.
   PubMed Web of Science ®Google Scholar
• Richart L, Carrillo-de Santa Pau E, Río-Machín A, et al. BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. Nat Commun. 2016;7(1):10153.
   PubMedGoogle Scholar
• Thomas LR, Wang Q, Grieb BC, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58(3):440–452.
   PubMed Web of Science ®Google Scholar
• Kress TR, Sabò A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer. 2015;15(10):593–607.
   PubMed Web of Science ®Google Scholar
• Sabò A, Amati B. Genome recognition by MYC. Cold Spring Harb Perspect Med. 2014;4:pii: a014191.
   Web of Science ®Google Scholar
• Liang K, Smith ER, Aoi Y, et al. Targeting processive transcription elongation via SEC disruption for MYC-induced cancer therapy. Cell. 2018;175(3):766–779.e17.
   PubMed Web of Science ®Google Scholar
• Lin C, Smith ER, Takahashi H, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell. 2010;37(3):429–437.
   PubMed Web of Science ®Google Scholar
• Rahl PB, Lin CY, Seila AC, et al. c-Myc regulates transcriptional pause release. Cell. 2010;141(3):432–445.
   PubMed Web of Science ®Google Scholar
• Rahl PB, Young RA. MYC and transcription elongation. Cold Spring Harb Perspect Med. 2014;4(1):a020990.
   PubMed Web of Science ®Google Scholar
• Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56–67.
   PubMed Web of Science ®Google Scholar
• Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68–79.
   PubMed Web of Science ®Google Scholar
• Sabò A, Kress TR, Pelizzola M, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014;511(7510):488–492.
   PubMed Web of Science ®Google Scholar
• Tesi A, de Pretis S, Furlan M, et al. An early Myc-dependent transcriptional program underlies enhanced macromolecular biosynthesis and cell growth during B-cell activation. EMBO Rep. 2019;20(9):e47987.
   PubMedGoogle Scholar
• Kress TR, Pellanda P, Pellegrinet L, et al. Identification of MYC-dependent transcriptional programs in oncogene-addicted liver tumors. Cancer Res. 2016;76(12):3463–3472.
   PubMed Web of Science ®Google Scholar
• Sabò A, Amati B. BRD4 and MYC-clarifying regulatory specificity. Science. 2018;360(6390):713–714.
   PubMed Web of Science ®Google Scholar
• Walz S, Lorenzin F, Morton J, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014;511(7510):483–487.
   PubMed Web of Science ®Google Scholar
• Tu WB, Shiah Y-J, Lourenco C, et al. MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell. 2018;34(4):579–595.e8.
   PubMed Web of Science ®Google Scholar
• Poole CJ, van Riggelen J. MYC-master regulator of the cancer epigenome and transcriptome. Genes (Basel). 2017;8(5):142.
   Web of Science ®Google Scholar
• Kaur M, Cole MD. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res. 2013;73(2):695–705.
   PubMed Web of Science ®Google Scholar
• Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008;456(7224):971–975.
   PubMed Web of Science ®Google Scholar
• Cowling VH, Cole MD. The Myc transactivation domain promotes global phosphorylation of the RNA Polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol. 2007;27(6):2059–2073.
   PubMed Web of Science ®Google Scholar
• Elkon R, Loayza-Puch F, Korkmaz G, et al. Myc coordinates transcription and translation to enhance transformation and suppress invasiveness. EMBO Rep. 2015;16(12):1723–1736.
   PubMed Web of Science ®Google Scholar
• Cole MD, Cowling VH. Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat Rev Mol Cell Biol. 2008;9(10):810–815.
   PubMed Web of Science ®Google Scholar
• Pourdehnad M, Truitt ML, Siddiqi IN, et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci. 2013;110(29):11988–11993.
   PubMed Web of Science ®Google Scholar
• Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012;3:228.
   PubMed Web of Science ®Google Scholar
• Koh CM, Bezzi M, Low DHP, et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015;523(7558):96–100.
   PubMed Web of Science ®Google Scholar
• van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer.. 2010;10(4):301–309.
   PubMed Web of Science ®Google Scholar
• Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci. 1997;94(13):6658–6663.
   PubMed Web of Science ®Google Scholar
• Doherty JR, Yang C, Scott KEN, et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 2014;74(3):908–920.
   PubMed Web of Science ®Google Scholar
• Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA. 1993;90(16):7804–7808.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang T-C, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–765.
   PubMed Web of Science ®Google Scholar
• Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849(5):506–516.
   PubMed Web of Science ®Google Scholar
• García-Gutiérrez L, Delgado MD, León J. MYC oncogene contributions to release of cell cycle brakes. Genes. 2019;10(3):244.
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227–231.
   PubMed Web of Science ®Google Scholar
• Xu Y, Poggio M, Jin HY, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019;25(2):301–311.
   PubMed Web of Science ®Google Scholar
• Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12(15):2424–2433.
   PubMed Web of Science ®Google Scholar
• Schmitt CA. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer. 2003;3(4):286–295.
   PubMed Web of Science ®Google Scholar
• Bouchard C, Lee S, Paulus-Hock V, et al. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev. 2007;21:2775–2787.
   PubMed Web of Science ®Google Scholar
• Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27(50):6462–6472.
   PubMed Web of Science ®Google Scholar
• Cai Q, Medeiros LJ, Xu X, et al. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015;6(36):38591–38616.
   PubMedGoogle Scholar
• Grandori C, Wu K-J, Fernandez P, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003;17(13):1569–1574.
   PubMed Web of Science ®Google Scholar
• Campaner S, Doni M, Hydbring P, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2010;12(1):54–59.
   PubMed Web of Science ®Google Scholar
• van Riggelen J, Felsher DW. Myc and a Cdk2 senescence switch. Nat Cell Biol. 2010;12(1):7–9.
   PubMed Web of Science ®Google Scholar
• Pérez-Roger I, Solomon DL, Sewing A, et al. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene. 1997;14(20):2373–2381.
   PubMed Web of Science ®Google Scholar
• Wu C-H, van Riggelen J, Yetil A, et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA. 2007;104(32):13028–13033.
   PubMed Web of Science ®Google Scholar
• Alonso S, Alcoceba M, Magnano L, et al. Incidence, risk factors and prognosis of transformation in follicular lymphoma: a multicentre retrospective analysis of 1763 patients from the Geltamo Spanish Lymphoma Cooperative Group. Blood. 2015;126:3944.
   Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5165–5169.
   PubMed Web of Science ®Google Scholar
• Janikova A, Bortlicek Z, Campr V, et al. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Ann Hematol. 2018;97(4):669–678.
   PubMed Web of Science ®Google Scholar
• Musilova K, Devan J, Cerna K, et al. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood. 2018;132(22):2389–2400.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci. 2002;99(13):8886–8891.
   PubMed Web of Science ®Google Scholar
• Aukema SM, van Pel R, Nagel I, et al. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. Histopathology. 2017;71(6):960–971.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–140.
   PubMed Web of Science ®Google Scholar
• Kawasaki C, Ohshima K, Suzumtya J, et al. Rearrangements of Bcl-1, Bcl-2, Bcl-6, and C-Myc in diffuse large B-cell lymphomas. Leuk Lymph. 2001;42:1099–1106.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9(1):55–61.
   PubMed Web of Science ®Google Scholar
• Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3152–3162.
   PubMed Web of Science ®Google Scholar
• Chisholm KM, Bangs CD, Bacchi CE, et al. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39(3):294–303.
   PubMed Web of Science ®Google Scholar
• Karube K, Campo E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol. 2015;52(2):97–106.
   PubMed Web of Science ®Google Scholar
• Kridel R, Mottok A, Farinha P, et al. Cell of origin of transformed follicular lymphoma. Blood. 2015;126(18):2118–2127.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–3401.
   PubMed Web of Science ®Google Scholar
• Scandurra M, Rossi D, Deambrogi C, et al. Genomic profiling of Richter’s syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol. 2010;28(2):62–67.
   PubMed Web of Science ®Google Scholar
• Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011;117(23):6227–6236.
   PubMed Web of Science ®Google Scholar
• Maeshima AM, Taniguchi H, Toyoda K, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174(6):923–931.
   PubMed Web of Science ®Google Scholar
• Rossi D. MYC addiction in chronic lymphocytic leukemia. Leuk Lymph. 2013;54:905–906.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761–2772.
   PubMed Web of Science ®Google Scholar
• Lovec H, Grzeschiczek A, Kowalski MB, et al. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13(15):3487–3495.
   PubMed Web of Science ®Google Scholar
• Schuster C, Berger A, Hoelzl MA, et al. The cooperating mutation or “second hit” determines the immunologic visibility toward MYC-induced murine lymphomas. Blood. 2011;118(17):4635–4645.
   PubMed Web of Science ®Google Scholar
• Lefebure M, Tothill RW, Kruse E, et al. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. Nat Commun. 2017;8(1):14581.
   PubMedGoogle Scholar
• García-Ramírez I, Tadros S, González-Herrero I, et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood. 2017;129(19):2645–2656.
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017;31(2):37–42.
   PubMed Web of Science ®Google Scholar
• De Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(5):1087–1090.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Holmes AB, Viganotti M, et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2017;114(14):E2911–E2919.
   PubMed Web of Science ®Google Scholar
• Mihailovich M, Bremang M, Spadotto V, et al. miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat Commun. 2015;6(1):8725.
   PubMedGoogle Scholar
• Zhang W, Kater AP, Widhopf GF, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci. 2010;107(44):18956–18960.
   PubMed Web of Science ®Google Scholar
• Wang W-G, Liu Z-B, Jiang X-N, et al. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma. Histopathology. 2017;71(5):778–785.
   PubMed Web of Science ®Google Scholar
• Gibson SE, Leeman-Neill RJ, Jain S, et al. Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene. Br J Haematol. 2016;175(1):173–175.
   PubMed Web of Science ®Google Scholar
• Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94(3):193–205.
   PubMed Web of Science ®Google Scholar
• Devan J, Janikova A, Mraz M. New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs. Semin Oncol. 2018;45(5-6):291–302.
   PubMed Web of Science ®Google Scholar
• Coelho V, Krysov S, Ghaemmaghami AM, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci. 2010;107(43):18587–18592.
   PubMed Web of Science ®Google Scholar
• Radcliffe CM, Arnold JN, Suter DM, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007;282(10):7405–7415.
   PubMed Web of Science ®Google Scholar
• Krysov S, Potter KN, Mockridge CI, et al. Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood. 2010;115(21):4198–4205.
   PubMed Web of Science ®Google Scholar
• Linley A, Krysov S, Ponzoni M, et al. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. 2015;126(10):1902–1910.
   Google Scholar
• Cha S-C, Qin H, Kannan S, et al. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol. 2013;190(9):4887–4898.
   PubMed Web of Science ®Google Scholar
• Sachen KL, Strohman MJ, Singletary J, et al. Self-antigen recognition by follicular lymphoma B-cell receptors. Blood. 2012;120(20):4182–4190.
   PubMed Web of Science ®Google Scholar
• Casola S, Perucho L, Tripodo C, et al. The B‐cell receptor in control of tumor B‐cell fitness: biology and clinical relevance. Immunol Rev. 2019;288(1):198–213.
   PubMed Web of Science ®Google Scholar
• Varano G, Raffel S, Sormani M, et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. Nature. 2017;546(7657):302–306.
   PubMed Web of Science ®Google Scholar
• Seitz V, Butzhammer P, Hirsch B, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS ONE. 2011;6(11):e26837.
   PubMed Web of Science ®Google Scholar
• Moyo TK, Wilson CS, Moore DJ, et al. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene. 2017;36(32):4653–4661.
   PubMed Web of Science ®Google Scholar
• Psathas JN, Doonan PJ, Raman P, et al. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood. 2013;122(26):4220–4229.
   PubMed Web of Science ®Google Scholar
• Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2015;29(5):1004–1017.
   PubMed Web of Science ®Google Scholar
• Tao J, Zhao X, Tao J. c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies. Cell Cycle. 2014;13(2):191–198.
   PubMed Web of Science ®Google Scholar
• Chang T-C, Yu D, Lee Y-S, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43–50.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen X, Lin J, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012;31(24):3002–3008.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell. 2012;22(4):506–523.
   PubMed Web of Science ®Google Scholar
• Brenner C, Deplus R, Didelot C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 2005;24(2):336–346.
   PubMed Web of Science ®Google Scholar
• Poole CJ, Zheng W, Lodh A, et al. DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt’s lymphoma. Oncotarget. 2017;8(44):76898–76920.
   PubMedGoogle Scholar
• O’Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839–843.
   PubMed Web of Science ®Google Scholar
• El Baroudi M, Corà D, Bosia C, et al. A curated database of miRNA mediated feed-forward loops involving MYC as master regulator. PLoS ONE. 2011;6(3):e14742.
   PubMed Web of Science ®Google Scholar
• Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9):1060–1065.
   PubMed Web of Science ®Google Scholar
• Inomata M, Tagawa H, Guo Y-M, et al. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2008;113(2):396–402.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pastore A, Deshpande AJ, et al. 3’UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle. 2009;8(21):3592–3600.
   PubMed Web of Science ®Google Scholar
• Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405–414.
   PubMed Web of Science ®Google Scholar
• Yang L-T, Li X-X, Qiu S-Q, et al. Micro RNA-19a suppresses thrombospondin-1 in CD35+ B cells in the intestine of mice with food allergy. Am J Transl Res. 2016;8(12):5503–5511.
   PubMed Web of Science ®Google Scholar
• Ivanovska I, Ball AS, Diaz RL, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol. 2008;28(7):2167–2174.
   PubMed Web of Science ®Google Scholar
• Sampath D, Calin GA, Puduvalli VK, et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood. 2009;113(16):3744–3753.
   PubMed Web of Science ®Google Scholar
• Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67(20):9762–9770.
   PubMed Web of Science ®Google Scholar
• Jiang S, Yan W, Wang SE, et al. Let-7 suppresses B cell activation through restricting the availability of necessary nutrients. Cell Metab. 2018;27(2):393–403.e4.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Schelter J, Burchard J, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007;27(6):2240–2252.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–13949.
   PubMed Web of Science ®Google Scholar
• Chen RW, Bemis LT, Amato CM, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 2008;112(3):822–829.
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113(26):6669–6680.
   PubMed Web of Science ®Google Scholar
• Lal A, Navarro F, Maher CA, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3’UTR microRNA recognition elements. Mol Cell. 2009;35(5):610–625.
   PubMed Web of Science ®Google Scholar
• Schneider C, Setty M, Holmes AB, et al. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci USA. 2014;111(22):8185–8190.
   PubMed Web of Science ®Google Scholar
• Bartolomé-Izquierdo N, de Yébenes VG, Álvarez-Prado AF, et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood. 2017;129:2408–2419.
   PubMed Web of Science ®Google Scholar
• Mott JL, Kobayashi S, Bronk SF, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26(42):6133–6140.
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590–11593.
   PubMed Web of Science ®Google Scholar
• Zauli G, Voltan R, di Iasio MG, et al. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 2011;17(9):2712–2724.
   PubMed Web of Science ®Google Scholar
• Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582(10):1564–1568.
   PubMed Web of Science ®Google Scholar
• Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007;67(4):1424–1429.
   PubMed Web of Science ®Google Scholar
• Kim J, Jeong D, Nam J, et al. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma. Gene. 2015;558(1):173–180.
   PubMed Web of Science ®Google Scholar
• Jeong D, Kim J, Nam J, et al. MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas. Leukemia. 2015;29(9):1868–1874.
   PubMed Web of Science ®Google Scholar
• Wong K-Y, Yim R-H, Kwong Y-L, et al. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol. 2013;6(1):16.
   PubMedGoogle Scholar
• Mraz M, Chen L, Rassenti LZ, et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014;124(1):84–95.
   PubMed Web of Science ®Google Scholar
• Lin Y-C, Kuo M-W, Yu J, et al. c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Mol Biol Evolut. 2008;25(10):2189–2198.
   PubMed Web of Science ®Google Scholar
• Vargova K, Curik N, Burda P, et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011;117(14):3816–3825.
   PubMed Web of Science ®Google Scholar
• Wang Q-M, Lian G-Y, Song Y, et al. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019;231:116335.
   PubMed Web of Science ®Google Scholar
• Lwin T, Zhao X, Cheng F, et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest. 2013;123:4612–4626.
   PubMed Web of Science ®Google Scholar
• Zhao Z-N, Bai J-X, Zhou Q, et al. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS ONE. 2012;7(9):e45133.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu M, Zhu H, et al. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level. Int J Oncol. 2010;37(5):1315–1321.
   PubMed Web of Science ®Google Scholar
• Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282(4):2135–2143.
   PubMed Web of Science ®Google Scholar
• Johnson DG. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog. 2000;27(3):151–157.
   PubMed Web of Science ®Google Scholar
• Coller HA, Forman JJ, Legesse-Miller A. “Myc’ed messages”: myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet. 2007;3(8):e146.
   PubMed Web of Science ®Google Scholar
• Jackstadt R, Hermeking H. MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta. 2015;1849(5):544–553.
   PubMed Web of Science ®Google Scholar
• Aguda BD, Kim Y, Piper-Hunter MG, et al. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA. 2008;105(50):19678–19683.
   PubMed Web of Science ®Google Scholar
• Kminkova J, Mraz M, Zaprazna K, et al. Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. Carcinogenesis. 2014;35(5):992–1002.
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Leyland R, Meyer-Hermann M, et al. MicroRNA-155 controls affinity-based selection by protecting c-MYC + B cells from apoptosis. J Clin Invest. 2015;126(1):377–388.
   PubMed Web of Science ®Google Scholar
• Knies-Bamforth UE, Fox SB, Poulsom R, et al. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res. 2004;64(18):6563–6570.
   PubMed Web of Science ®Google Scholar
• Sodir NM, Evan GI. Finding cancer's weakest link. Oncotarget. 2011;2(12):1307–1313.
   PubMedGoogle Scholar
• Mezquita P, Parghi SS, Brandvold KA, et al. Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. Oncogene. 2005;24(5):889–901.
   PubMed Web of Science ®Google Scholar
• Izreig S, Samborska B, Johnson RM, et al. The miR-17 ∼ 92 microRNA cluster is a global regulator of tumor metabolism. Cell Rep. 2016;16(7):1915–1928.
   PubMed Web of Science ®Google Scholar
• Mu P, Han Y-C, Betel D, et al. Genetic dissection of the miR-17 ∼ 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23(24):2806–2811.
   PubMed Web of Science ®Google Scholar
• Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839–2849.
   PubMed Web of Science ®Google Scholar
• Psathas JN, Thomas-Tikhonenko A. MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med. 2014;4:a014175.
   PubMed Web of Science ®Google Scholar
• Liu W, Le A, Hancock C, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA. 2012;109(23):8983–8988.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Edmonds MD, Liang S, et al. miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. Hum Pathol. 2016;50:118–126.
   PubMed Web of Science ®Google Scholar
• Ntoufa S, Papakonstantinou N, Apollonio B, et al. B cell anergy modulated by TLR1/2 and the miR-17 ∼ 92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. J Immunol. 2016;196:4410–4417.
   PubMed Web of Science ®Google Scholar
• Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22:167–179.
   PubMed Web of Science ®Google Scholar
• Mottok A, Jurinovic V, Farinha P, et al. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood. 2018;131(2):226–235.
   PubMed Web of Science ®Google Scholar
• Gascoyne DM, Banham AH. The significance of FOXP1 in diffuse large B-cell lymphoma. Leuk Lymph. 2017;58(5):1037–1051.
   PubMed Web of Science ®Google Scholar
• Cerna K, Oppelt J, Chochola V, et al. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33:403–419.
   PubMed Web of Science ®Google Scholar
• Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23(6):1159–1163.
   PubMed Web of Science ®Google Scholar
• Cerna K, Mraz M. p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1. Oncotarget. 2018;9(92):36409–36410.
   PubMedGoogle Scholar
• Van Roosbroeck K, Bayraktar R, Calin S, et al. The involvement of microRNA in the pathogenesis of Richter syndrome. Haematologica. 2019;104(5):1004–1015.
   PubMed Web of Science ®Google Scholar
• Balatti V, Tomasello L, Rassenti LZ, et al. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018;132(20):2179–2182.
   PubMed Web of Science ®Google Scholar
• Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136(2):286–293.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124(24):4622–4632.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1):24–31.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459.
   PubMed Web of Science ®Google Scholar
• Miyaoka M, Kikuti YY, Carreras J, et al. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Mod Pathol. 2018;31(2):313–326.
   PubMed Web of Science ®Google Scholar
• Katsushima H, Fukuhara N, Konosu-Fukaya S, et al. Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation? Leuk Lymph. 2018;59:758–762.
   PubMed Web of Science ®Google Scholar
• López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun. 2019;10(1):1459.
   PubMedGoogle Scholar
• Iaccarino I. lncRNAs and MYC: an intricate relationship. Int J Mol Sci. 2017;18:1497.
   Web of Science ®Google Scholar
• Doose G, Haake A, Bernhart SH, et al. MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 2015;112(38):E5261–5270.
   PubMed Web of Science ®Google Scholar
• Yustein JT, Liu Y-C, Gao P, et al. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci USA. 2010;107(8):3534–3539.
   PubMed Web of Science ®Google Scholar
• Hart JR, Roberts TC, Weinberg MS, et al. MYC regulates the non-coding transcriptome. Oncotarget. 2014;5(24):12543–12554.
   PubMedGoogle Scholar
• Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Sig Transduct Target Ther. 2018;3(1):5.
   PubMedGoogle Scholar
• Beaulieu M-E, Jauset T, Massó-Vallés D, et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med. 2019;11:pii: eaar5012.
   Web of Science ®Google Scholar
• Koh CM, Sabò A, Guccione E. Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays. 2016;38(3):266–275.
   PubMed Web of Science ®Google Scholar
• Balaji KC, Koul H, Mitra S, et al. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology. 1997;50(6):1007–1015.
   PubMed Web of Science ®Google Scholar
• Iversen PL, Arora V, Acker AJ, et al. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res. 2003;9(7):2510–2519.
   PubMed Web of Science ®Google Scholar
• Sekhon HS, London CA, Sekhon M, et al. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer. 2008;60(3):347–354.
   PubMed Web of Science ®Google Scholar
• Giles RV, Spiller DG, Clark RE, et al. Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev. 1999;9(2):213–220.
   PubMedGoogle Scholar
• Derenzini E, Mondello P, Erazo T, et al. BET inhibition-induced GSK3β feedback enhances lymphoma vulnerability to PI3K inhibitors. Cell Rep. 2018;24(8):2155–2166.
   PubMed Web of Science ®Google Scholar
• Harrington CT, Sotillo E, Robert A, et al. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. 2019;33:2429–2441.
   PubMed Web of Science ®Google Scholar
• Boudny M, Zemanova J, Khirsariya P, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019. DOI:10.3324/haematol.2018.203430
   PubMed Web of Science ®Google Scholar
• Wall M, Poortinga G, Stanley KL, et al. The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov. 2013;3(1):82–95.
   PubMed Web of Science ®Google Scholar
• Miluzio A, Beugnet A, Grosso S, et al. Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell. 2011;19(6):765–775.
   PubMed Web of Science ®Google Scholar
• Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22(1):51–65.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Knorr KLB, et al. 4EBP1/c-MYC/PUMA and NF-kB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood. 2016;127(22):2711–2722.
   PubMed Web of Science ®Google Scholar